CloudBlue and CloudSense Strike a Strategic Relationship to Connect Telecommunications Providers With a Broad Ecosystem of ICT Channel Partners via a New Digital Catalog
5.4.2022 16:00:00 EEST | Business Wire | Press release
CloudBlue, a leading cloud ecosystem technology company which powers some of the largest commerce platforms for cloud and IT channel products globally, today announced an agreement with CloudSense, provider of one of the market’s most powerful Configure, Price, Quote (CPQ) platforms.
CloudSense has a well-established footprint within the telecommunications industry, with customers including prominent regional and international brands such as BT, Starhub and Vodafone Ziggo. By providing a direct integration from CloudBlue Connect™ to the CloudSense CPQ platform, CloudSense’s community of telecommunications customers will be able to tap into a new pool of ICT offerings and scale their business faster than ever.
The direct integration between CloudBlue Connect and CloudSense CPQ will allow telecommunications providers to enrich their own portfolio of B2B solutions more efficiently. This new integration will streamline their ability to procure traditional ICT services and bundle them into a wide range of innovative B2B XaaS solutions, which can be sold by a direct sales force or a network of resellers. Telecommunications and ICT providers will be able to create simple and easy quotes and contracts via CloudSense CPQ without the need to rekey orders or engage in manual processes.
CloudBlue will benefit from this new relationship through expanded exposure of its 200+ XaaS digital solutions to the telecommunications community. The initiative clears the way for CloudSense’s customers to access the tools they need to provide businesses of all sizes with the anything-as-a-service (XaaS) offerings that have surged in demand post-pandemic.
“As telcos look for new ways to diversify their offerings, cross-platform integration becomes key to providing end-users the best in Cloud. CloudBlue’s new agreement with CloudSense marks the latest in a series of innovative and creative relationships forming across Cloud to the continued delight of channel partners,” said Tarik Faouzi, senior vice president of CloudBlue.
“CloudSense recognizes the importance of bringing to market innovative solutions that address challenges in our focus verticals. We believe the CloudSense-CloudBlue agreement establishes the first Marketplace of its kind to facilitate commercial innovation across the communications ecosystem. This will give communications service providers broader access to a global network of channel partners and remove the need for manual input when drafting quotes and contracts,” said Jonathan English, CEO, CloudSense.
About CloudSense
The CloudSense Configure, Price, Quote (CPQ) application suite powers increased productivity and profits for ambitious enterprises allowing them to launch faster, sell more and fulfill orders faultlessly. Its growing global community of customers rely on CloudSense to deliver sales transformation within the Communications and Media industries. Leading brands including Telefonica, Telstra, and Informa use CloudSense's portfolio of applications to streamline the entire customer lifecycle, providing a better customer experience while improving business performance. To find out more, visit CloudSense.com
About CloudBlue
CloudBlue helps businesses succeed in the as-a-service economy and accelerate time to revenue by managing subscription and billing, vendor and product information, and partner onboarding across multiple channels. Through its leading ecosystem orchestration platform, CloudBlue enables companies to create their own ecosystems, as well as connect vendor and go-to-market ecosystems, automating the distribution of traditional and digital products and services across partners in the digital supply chain. CloudBlue serves more than 180 companies around the globe and powers the world’s largest cloud B2B marketplaces, which represent 30 million B2B cloud subscriptions. Learn more about CloudBlue at www.cloudblue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005045/en/
Contact information
Andrew Zelinko
CloudBlue
Andrew.Zelinko@cloudblue.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom